Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Clinical evidence

VX19-147-101

71 evidence topics · 9 sources

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Primary purpose“Treatment”
Allocation“N/A”
Interventional model“Single Group Assignment”
Masking“None (Open Label)”
Phase“Phase 2”
Enrollment“16”
Eligibility criteria
Inclusion criteria in the protocol: biopsy, stable background therapy, eGFR, and UPCR
Treatment
Study outcomes
Rationale for using percent change in UPCR as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants by cohort in the posted results
MeasureQuoted record
Enrollment (actual)“16”
Started“16”
Cohort 1“3”
Cohort 2“13”
AUC0-24hr, overall number of participants analyzed“13”
Description of analysis sets
Results
Participant disposition
Participant flow in the posted results
MilestoneQuoted record
Started“16”
Cohort 1“3”
Cohort 2“13”
Completed“15”
Not completed“1”
Reason not completed“Withdrawal of consent (not due to adverse event)”
Baseline characteristics
Demographic and clinical characteristics at baseline (Table 1)
CharacteristicTotal (N=16)Nephrotic-range proteinuria (N=3)Subnephrotic-range proteinuria (N=13)
Age, years, mean ±SD“38.8±14.5”“45.0±10.5”“37.3±15.2”
Male, no. (%)“7 (44)”“1 (33)”“6 (46)”
Female, no. (%)“9 (56)”“2 (67)”“7 (54)”
APOL1 genotype G1/G1, no. (%)“9 (56)”“3 (100)”“6 (46)”
APOL1 genotype G2/G2, no. (%)“1 (6)”“0”“1 (8)”
APOL1 genotype G1/G2, no. (%)“6 (38)”“0”“6 (46)”
Body-mass index, mean ±SD“29.6±6.4”“32.7±6.4”“28.9±6.4”
Urinary protein-to-creatinine ratio, mean ±SD“2.08±0.90”“3.47±1.07”“1.77±0.49”
Estimated GFR, ml/min/1.73 m2, mean ±SD“51.2±14.0”“51.4±22.2”“51.2±12.8”
ACE inhibitor ≥28 days before day 1, no. (%)“8 (50)”“1 (33)”“7 (54)”
Angiotensin-receptor blocker ≥28 days before day 1, no. (%)“7 (44)”“3 (100)”“4 (31)”
Immunosuppressants ≥28 days before day 1, no. (%)“4 (25)”“1 (33)”“3 (23)”
Race and ethnicity in the posted results
CharacteristicCohort 1 (N=3)Cohort 2 (N=13)
Black or African American“3”“13”
White“0”“0”
Not Hispanic or Latino“3”“13”
Efficacy results
Primary endpoint: percent change from baseline in UPCR at week 13 (Table 2)
MeasureTotal (N=13)Nephrotic-range proteinuria (N=3)Subnephrotic-range proteinuria (N=10)
Mean UPCR at baseline, ±SD“2.21±0.95”“3.47±1.07”“1.84±0.52”
Mean UPCR at week 13, ±SD“1.27±0.73”“1.83±0.58”“1.10±0.71”
Geometric percent change from baseline at week 13 (95% CI)“−47.6 (−60.0 to −31.3)”“−47.7 (−70.1 to −8.5)”“−47.5(−63.4 to −24.6)”
Pharmacokinetics: AUC0-24h at week 5 (secondary outcome)
Health-related quality of life and patient-reported outcomes
SF-36 results

No evidence found.

Safety results
Adverse events (Table 3)
Event, no. (%)Total (N=16)Nephrotic-range proteinuria (N=3)Subnephrotic-range proteinuria (N=13)
Any adverse event“15 (94)”“3 (100)”“12 (92)”
Mild“7 (44)”“1 (33)”“6 (46)”
Moderate“8 (50)”“2 (67)”“6 (46)”
Serious adverse event“1 (6)”“0”“1 (8)”
Headache“4 (25)”“1 (33)”“3 (23)”
Back pain“3 (19)”“0”“3 (23)”
Nausea“3 (19)”“1 (33)”“2 (15)”
Decrease in blood bicarbonate level“2 (12)”“0”“2 (15)”
Diarrhea“2 (12)”“1 (33)”“1 (8)”
Dizziness“2 (12)”“0”“2 (15)”
Dyspepsia“2 (12)”“0”“2 (15)”
Fatigue“2 (12)”“0”“2 (15)”
Deaths, serious adverse events, and other adverse events in the posted results
Measure, affected / at risk (%)Cohort 1Cohort 2Total
All-cause mortality“0/3 (0.00%)”“0/13 (0.00%)”“0/16 (0.00%)”
Serious adverse events, total“0/3 (0.00%)”“1/13 (7.69%)”“1/16 (6.25%)”
Other (not including serious) adverse events, total“3/3 (100.00%)”“12/13 (92.31%)”“15/16 (93.75%)”
Adverse events in investigations and cardiac disorders in the posted results
EventTotal, affected / at risk (%)
Blood bicarbonate decreased“2/16 (12.50%)”
Blood creatine phosphokinase increased“1/16 (6.25%)”
Electrocardiogram ST segment depression“1/16 (6.25%)”
Gamma-glutamyltransferase increased“1/16 (6.25%)”
Transaminases increased“1/16 (6.25%)”
Palpitations“1/16 (6.25%)”
Study limitations
Summary: study limitations

VX19-147-101 was a single-group, open-label study without a placebo group; the protocol states that a placebo arm was omitted because of a “very low likelihood of spontaneous remission”. Sixteen participants were enrolled, and the primary analysis included the 13 participants with at least 80% adherence; the planned sample size of 10 was chosen for the precision of the geometric mean estimate, without a power calculation. Treatment lasted 13 weeks, and the off-treatment follow-up (part B) included 9 participants. The primary endpoint was the percent change from baseline in the urinary protein-to-creatinine ratio at week 13, and the secondary endpoints were safety and pharmacokinetics. Eligibility required biopsy-proven focal segmental glomerulosclerosis, two APOL1 variants, age 18 to 65 years, and an estimated GFR of at least 30 mL/min/1.73 m2 (±10%), so other APOL1-mediated kidney disease phenotypes were not studied; only 3 participants had nephrotic-range proteinuria. All 16 participants were Black or African American and were enrolled at sites in France, the United Kingdom, and the United States. The protocol listed SF-36 as an exploratory endpoint, and no SF-36 results were located in the published report or the posted results.